Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed through laboratory testing of tissue samples.
- People who have completed at least 3 cycles of platinum-based chemotherapy (with or without additional drugs bevacizumab and/or a PARP inhibitor) as their first course of treatment.
- People for whom at least 6 months have passed since their last dose of platinum-based chemotherapy.
- People for whom upfront surgery to remove cancer (called secondary cytoreductive surgery) has been assessed as not currently feasible.
- People with a general health and activity level rated between 0 and 2 on a standard medical scale (meaning able to carry out at least some daily activities), assessed within 28 days before joining the trial.
- People with adequate bone marrow, kidney, liver, and nerve function, confirmed within 28 days before treatment begins.
Who may not be able to join:
- People whose ovarian tumour is a non-epithelial type or classified as "borderline" (low malignant potential).
- People who have had another cancer diagnosis within the last five years (except for certain early-stage or low-risk cancers such as basal or squamous cell skin cancer, early in-situ breast cancer, or a specific low-grade early uterine cancer without spread to blood or lymph vessels).
- People who have received more than one line (course) of chemotherapy.
- People whose cancer has come back and is resistant or non-responsive to platinum-based chemotherapy.
- People who are experiencing a second or later relapse of their cancer.
- People who have medical reasons that make surgery unsafe, such as unresolved low platelet counts or a bowel obstruction occurring within the 4 weeks before enrolment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ka Yu Tse, The University of Hong Kong
Phone: 852-22554265
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete resection rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.